To evaluate if these results are generalizable to other cancer types and primary tumor samples, we tested the effect of imatinib on the KIT-mutant gastrointestinal stromal tumor (GIST) cell line GIST-T1 (Fig. 1d) and the effects of gefitinib on the EGFR-mutant lung cancer cell line PC9 (Fig. 1e). The gene discussed is EGFR; the disease is lung cancer.